// App-Quantinova.ai

: Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naïve prostate cancer (mCNPC).

Researchers

Presenter

  • Susan Feyerabend

Principal Investigators

  • Fred Saad

  • Tracy Li

  • Tetsuro Ito

  • Joris Diels

  • Suzy Van Sanden

  • Peter De Porre

  • Seye Abogunrin

  • Maria Koufopoulou

  • Karim Fizazi

Medical Centers

  • Studienpraxis Urologie, Nurtingen, Germany

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Janssen Global Services, Raritan, NJ

  • Janssen-Cilag, Buckinghamshire, United Kingdom

  • Janssen Research & Development, Beerse, Belgium

  • Evidera, Inc., London, United Kingdom

  • Gustave Roussy Institute of Oncology, University of Paris-Sud, Villejuif, France

Locations

  • Germany

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01715285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved